H.C. Wainwright Thinks Agile Therapeutics’ Stock is Going to Recover


H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) today and set a price target of $4. The company’s shares opened today at $0.92, close to its 52-week low of $0.23.

Livnat noted:

“We had always believed the Products (DBRUP) directive to Agile—to go reformulate Twirla, show improved adhesion, then prove bioequivalence to the current patch or do a new Phase 3 —was unnecessary. Based on all the data we’ve seen, we have never had reason to believe Twirla has an adhesion problem, and likely has better benefit-risk than the only approved contraceptive patch, Ortho Evra (now branded-generic Xulane), which does 1.7M Rx/year despite high-dose CV risk, unique black box safety warnings, and likely similar detachment rates (see below).”

According to TipRanks.com, Livnat is a 2-star analyst with an average return of 1.6% and a 49.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.

Agile Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.

See today’s analyst top recommended stocks >>

Based on Agile Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.34 million. In comparison, last year the company had a GAAP net loss of $7.1 million.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch for use in contraception. It offers its product candidate Twirla, which is an investigational non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts